Case Report: Treatment of Alectinib in NSCLC With Brain Metastasis Patient Refractory to Radiotherapy After Resistance to Crizotinib

BACKGROUND: Brain metastasis is the most common form of tumor recurrence after resistance to crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). The treatment of brain metastasis in patients with ALK-positive NSCLC requires a multidisciplinary ap...

Descripción completa

Detalles Bibliográficos
Autor principal: Zhang, Chunzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273575/
https://www.ncbi.nlm.nih.gov/pubmed/34262876
http://dx.doi.org/10.3389/fonc.2021.709188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273575/
https://www.ncbi.nlm.nih.gov/pubmed/34262876
http://dx.doi.org/10.3389/fonc.2021.709188

Ejemplares similares